Thermo Fisher Scientific (NYSE: TMO ) is expected to report Q3 earnings on Oct. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Thermo Fisher Scientific's revenues will grow 0.8% and EPS will grow 8.4%.
The average estimate for revenue is $3.00 billion. On the bottom line, the average EPS estimate is $1.16.
Last quarter, Thermo Fisher Scientific reported revenue of $3.11 billion. GAAP reported sales were 8.9% higher than the prior-year quarter's $2.85 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.22. GAAP EPS of $0.63 for Q2 were 53% lower than the prior-year quarter's $1.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 42.9%, 170 basis points better than the prior-year quarter. Operating margin was 13.1%, 70 basis points better than the prior-year quarter. Net margin was 7.5%, 1,080 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $12.28 billion. The average EPS estimate is $4.82.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 552 members out of 573 rating the stock outperform, and 21 members rating it underperform. Among 155 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 152 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $63.00.